Doximity Tops Q4 Guidance, Reports Record Free Cash Flow, Plans AI Investment Year
DOCS•Doximity’s fiscal Q4 revenue topped the high end of its guidance and delivered record free cash flow. Management announced an “AI investment year” with higher spending on AI products while cautioning that digital pharma advertising growth remains soft.
1. Q4 Performance Exceeds Forecast
Doximity closed fiscal 2026 Q4 with revenue above the high end of its guidance range, driven by subscription service growth, and generated record free cash flow. This performance strengthened liquidity and exceeded analysts’ consensus estimates.
2. “AI Investment Year” Strategy
Management designated the coming 12 months as an “AI investment year,” planning to ramp R&D and product development spending on machine learning tools, expert networks and clinical workflow enhancements to drive long-term growth.
3. Digital Pharma Advertising Outlook
Despite the overall revenue beat, management noted that near-term growth in the digital pharma advertising market is subdued, reflecting cautious client budgets and slower campaign rollouts.
Related News
Kohl's Chief People Officer Mari Steinmetz disposes of 242 common shares worth $4,026.31
Pembina Pipeline declares quarterly preferred share dividends, including CAD 0.41 for Series 1
